Labcorp's venture capital arm, Labcorp Venture Fund, focuses on strategic investments in healthcare, life science, oncology, and fem technology sectors. Its strategy is to partner with startups and founders across the healthcare continuum to advance innovative, data-driven, accessible, and personalized care, encompassing areas like diagnostics, precision medicine, digital health, and clinical trial optimization.
Portfolio
11
Fund Size
—
Top Stage
Series B
Last 12 Mo
4
Stage Distribution
Portfolio
11 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Prenosis | Series A | $20M | Jan 2026 |
| Precede Biosciences | Series B | $63.5M | Jan 2026 |
| Mercy BioAnalytics, Inc. | Series B | $59M | Sep 2025 |
| PreciseDx | Series B | $11M | Jun 2025 |
| PreciseDx | Series B | $20.7M | Aug 2024 |
| Acclinate | Series A | $7M | May 2024 |
| Evvy | Series A | $14M | Sep 2023 |
| Vital Bio | Series B | $48M | Jul 2023 |
| Epic Sciences, Inc. | Series F | $43M | Jun 2022 |
| Boston Microfluidics | Series A | $17.5M | Aug 2019 |
| ORIG3N, Inc. | Unknown | — | Jun 2017 |
Top Co-Investors
Eventide Asset Management2 shared
Arsenal Growth1 shared
Deerfield1 shared
UC Investments1 shared
Anzu Partners1 shared
Cencora Ventures1 shared
Inovia Capital1 shared
Illumina Ventures1 shared
UPMC Enterprises1 shared
Mirae Asset1 shared
S28 Capital1 shared
Alexandria Venture Investments1 shared
Bristol Myers Squibb1 shared
Osage University Partners1 shared
Lilly Asia Ventures1 shared
Sozo Ventures1 shared
iSelect Fund1 shared
Portfolia1 shared
Merck Global Health Innovation Fund1 shared
Last updated: 3 March 2026